A 52-year-old man with type 2 diabetes and hypertension presents for cardiovascular risk assessment. His lipid profile shows: Total cholesterol 280 mg/dL, LDL-C 180 mg/dL, HDL-C 35 mg/dL, Triglycerides 320 mg/dL. He is already on metformin and lisinopril. His estimated 10-year ASCVD risk is 18%. On examination, he has xanthomas on his Achilles tendons and eyelids. Which of the following is the most appropriate initial pharmacological intervention?

Explanation

## Clinical Assessment **Key Point:** This patient has multiple cardiovascular risk factors (diabetes, hypertension, elevated ASCVD risk) with significantly elevated LDL-C and low HDL-C. The presence of xanthomas indicates chronic hyperlipidemia and warrants aggressive lipid-lowering therapy. **High-Yield:** According to current ACC/AHA guidelines, patients with diabetes and LDL-C ≥70 mg/dL (or those with ASCVD risk ≥7.5%) require high-intensity statin therapy as first-line treatment. This patient's LDL-C of 180 mg/dL and ASCVD risk of 18% clearly meet criteria. ## Statin Selection Rationale | Feature | High-Intensity Statin | Moderate-Intensity | Low-Intensity | |---------|----------------------|-------------------|---------------| | LDL-C reduction | 50–55% | 30–49% | <30% | | Examples | Atorvastatin 80 mg, Rosuvastatin 20–40 mg | Atorvastatin 10–20 mg, Simvastatin 20–40 mg | Pravastatin 10–20 mg | | Indication | ASCVD, diabetes with risk factors | Moderate risk | Primary prevention, low risk | **Clinical Pearl:** Xanthomas are a sign of severe dyslipidemia and indicate the need for aggressive LDL-C reduction. Statins are the cornerstone of therapy and should be initiated first; additional agents (ezetimibe, PCSK9 inhibitors) are added only if LDL-C goals are not met on statin monotherapy. **Mnemonic:** **ASCVD Risk Tiers** — Atherosclerotic Cardiovascular Disease risk stratification: - Very high risk (prior ASCVD, diabetes with risk factors, LDL ≥70): High-intensity statin - High risk (10-year risk ≥7.5%): High-intensity statin - Moderate risk: Moderate-intensity statin - Low risk: Low-intensity or lifestyle ## Why Monotherapy First? Combination therapy (statin + ezetimibe + bempedoic acid) is reserved for patients who do not achieve LDL-C goals on statin monotherapy or who are statin-intolerant. This patient has not yet been tried on a statin, so combination therapy is premature. **Tip:** Remember the sequential approach: (1) High-intensity statin, (2) Add ezetimibe if LDL goal not met, (3) Add PCSK9 inhibitor or bempedoic acid if still not at goal.